Oncimmune
Stage
DivestitureTotal Raised
$2MInvestors Count
2Deal Terms
1Portfolio Exits
2Funding, Valuation & Revenue
3 Fundings
Oncimmune has raised $2M over 3 rounds.
Oncimmune's latest funding round was a Growth Equity for $2M on August 20, 2018.
Oncimmune's valuation in May 2016 was $96.87M.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
8/20/2018 | Growth Equity | $2M | 1 | |||
5/18/2016 | IPO | $96.87M | ||||
1/1/2007 | Unattributed VC |
Date | 8/20/2018 | 5/18/2016 | 1/1/2007 |
|---|---|---|---|
Round | Growth Equity | IPO | Unattributed VC |
Amount | $2M | ||
Investors | |||
Valuation | $96.87M | ||
Revenue | |||
Sources | 1 |
Oncimmune Deal Terms
1 Deal Term
Oncimmune's deal structure is available for 1 funding round, including their IPO from May 18, 2016.
Round | IPO |
|---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO |
Oncimmune Investors
2 Investors
Oncimmune has 2 investors. Harbert European Growth Capital invested in Oncimmune's Growth Equity funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
8/20/2018 | 8/20/2018 | 1 Growth Equity | Debt & Specialty Finance | United Kingdom | ||
Venture Capital | United Kingdom |
First funding | 8/20/2018 | |
|---|---|---|
Last Funding | 8/20/2018 | |
Investor | ||
Rounds | 1 Growth Equity | |
Board Seats | ||
Type | Debt & Specialty Finance | Venture Capital |
Location | United Kingdom | United Kingdom |
Oncimmune Acquisitions
1 Acquisition
Oncimmune acquired 1 company. Their latest acquisition was Protagen Diagnostics on March 19, 2019.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
3/19/2019 | Acquired | 1 |
Date | 3/19/2019 |
|---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired |
Sources | 1 |
Oncimmune Portfolio Exits
2 Portfolio Exits
Oncimmune has 2 portfolio exits. Their latest portfolio exit was OncImmune - Diagnostic Business on May 22, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
5/22/2023 | Divestiture | OncImmune - Diagnostic Business | 2 | ||
Date | 5/22/2023 | |
|---|---|---|
Exit | Divestiture | |
Companies | OncImmune - Diagnostic Business | |
Valuation | ||
Acquirer | ||
Sources | 2 |
Compare Oncimmune to Competitors
ErleaDx is a company that develops diagnostic products for the detection of lung cancer within the healthcare industry. Their main offering is a patented blood-based biomarker panel designed to detect lung cancer at an early stage. ErleaDx specializes in Point-Of-Care diagnostics for lung cancer screening, providing results in a matter of minutes. It was founded in 2021 and is based in Singapore.
Biodesix is a diagnostic solutions company that provides diagnostic tests and custom development services for patients with lung disease. Biodesix serves biopharmaceutical, life sciences, and research institutions with its diagnostic testing and development services. It was founded in 2005 and is based in Boulder, Colorado.
GRAIL focuses on early cancer detection within the medical technology sector. The company develops multi-cancer early detection (MCED) tests that analyze DNA in the bloodstream to identify potential cancer signals, using methylation analysis and machine-learning algorithms. GRAIL's services are directed towards the healthcare industry, providing diagnostic aids for oncology and contributing to cancer screening efforts. GRAIL was formerly known as PSC15. It was founded in 2016 and is based in Menlo Park, California.
Loading...